Assignment Report: Evaluation of the Medicines Transparency Alliance Phase 1, 2008-2010

Abstract

The Medicines Transparency Alliance (MeTA) was created in recognition of the key importance of access to medicines.These documents report on:

  • Establishing a framework for MeTA in pilot countries; gaining government commitment and establishing sectoral and national committees.
  • Delivering against the MeTA objectives in countries; progress towards data identification, disclosure, changes in practice and logframe objectives.
  • The genesis of MeTA
  • International governance; the management board, advisory group, secretariat, private sector and civil society.
  • The MeTA hypotheses

The future of MeTA is examined including:

  • Funding mechanisms and identification of new funders
  • Governance arrangements
  • Identification of new countries
  • Whether to continue support to existing countries
  • The design and identification of the international secretariat function
  • What might be different?

Citation

Ollier, E.; Gittins, N.; Collins, T.; Mubangizi, P.; Waddington, C.; Whitaker, D. Assignment Report: Evaluation of the Medicines Transparency Alliance Phase 1, 2008-2010. HDRC, UK (2010) 126 pp.

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.